Figure 3 | Scientific Reports

Figure 3

From: Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients

Figure 3

Cytokine measurements in PBMCs from RA patients and stratified for the IL-32 promoter SNP after stimulation with either Poly I:C and rhIL-1β or rhTNFα. (A) IL-6 protein concentration in PBMCs of RA patients with the TT- versus CC-genotype for the promoter SNP, at basal level and after stimulation. (B) IL-8 protein concentration in PBMCs of RA patients with the TT- versus the CC-genotype for the IL-32 promoter SNP, at basal level and after stimulation. Significant differences were observed after rhIL-1β stimulation between the CC- versus TT-genotype (p = 0.0335). (C) IL-1Ra protein concentration in PBMCs of RA patients with the TT- versus CC-genotype for the IL-32 promoter SNP at basal level as well as after stimulation. Statistical significance was shown by * when p < 0.05, GraphpadPrism V5.03. (n = 27 TT RA patients and n = 15 CC RA patients).

Back to article page